|Articles|May 8, 2018
The Missing Link in Amazon’s Healthcare Takeover
Author(s)Michelle Maskaly
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
Advertisement
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results
2
Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg
3
Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson
4
Novavax's Strategy Across Commercial, R&D, and Partnerships
5